Published :
Tables : 104
Figures : 67
Category : Healthcare
No. of Pages : 190
Report Code : HC-1201
Stem Cell Market Introduction: Stem Cell Market is estimated to value over USD 15.5 billion by 2027 end and is expected to register a CAGR over 8.5% during the forecast period 2020 to 2027. Market Insights: Advanced research in the development of biomaterial polymeric systems has resulted in a significant rise in recent years. These systems are instrumental in aiding the survival of stem cells which has boosted the market growth. Furthermore, advancements in the treatment of damaged tissues and diseased organs coupled with an increasing demand for regenerative medicines has propelled the market growth significantly. The adoption of stem cell has opened new opportunities for applications such as wound healing therapy which has assisted in the further augmentation of the market. The increased supply of biomaterial development used in stem cell transplantation and induced pluripotent stem cells (iPSCs) has revolutionised the stem cell sector. Such innovations allow researchers to create pluripotent stem cells from adult somatic cells which aid in preserving genetic information in these cells thus boosting the market growth. Based on the type of product, the market is categorised as adult stem cells, human embryonic stem cells, induced pluripotent stem cells and very small embryonic-like stem cells. The adult stem cell segment accounts for the largest market share and is predicted to continue this dominance during the forecast period. This is due to the low contamination risks linked to the minimal requirement of production labour, compatibility with the human body and sub-culturing. Pharmaceutical companies have profitable opportunities in the stem cell sector by initiating advancements in the identification of leading candidates thus allowing companies to develop novel drugs. Furthermore, extensive research has advanced the analysis of single-cell thus helping study the effects of drugs on cell differentiation. Additionally, the growing dependence of developing entities in cellular systems is projected to help the segment strengthen its market position in the upcoming years. Technology-wise, the market is bifurcated into cell acquisition, bone marrow harvest, apheresis, umbilical blood cord, cell production, therapeutic cloning, in-vitro fertilization, cell culture, isolation, expansion & sub-culture and cryopreservation. The cell production technology held the largest market share due to the current technological advancements aiming at satisfying the growing needs from different clinical applications. A soaring number of organ replacement approaches coupled with the rising demand for therapeutics has bolstered the market significantly. For instance, approximately 2200 transplant surgeries that were conducted in 2016 across the world were pancreas transplants. Depending on the type of therapy, the market is fragmented into autologous stem cell therapy and allogeneic stem cell therapy. Autologous stem cell therapy dominated the market concerning revenue generation in 2018. This is mainly attributed to the consumption of autologous products on a large scale owing to associative high compatibility. Additionally, meta-analytical studies on the effectiveness of autologous therapy for the treatment of lower limb disorders will propel the market further. Many companies are engaged in developing these autologous products for patients with sport-related injuries despite it being scrutinized by multiple government bodies. Regional Insights: The Asia Pacific region is projected to attain a remarkable CAGR over the forecast period. Developed economies like Australia, Singapore and Japan are extensively investing in the research and development projects which shall drive the market growth. Asia Pacific countries are likely to lead the rapidly evolving stem cell industry. Commercialization opportunities coupled with favourable regulatory policies bolster the market expansion. Japan, in particular, has initiated regulatory amendments related to regenerative medicine which has attracted international manufacturers to invest massively in the Japanese market. Key market players include Stemcell Technologies Inc., Celegene Corp., Osiris Therapeutics Inc., Biotime Inc., Advanced Cell Technology Inc. Cytori Therapeutics, Human Longevity Inc., Cynata, Promethera Biosciences, Mesoblast., Celgene Corporation, ReNeuron Group plc, Cytori Therapeutics, Inc., Cryo-Cell International Inc. Market Segmentation: By Product Adult Stem Cells Human Embryonic Stem Cells Induced Pluripotent Stem Cells (iPSCs) Very Small Embryonic-like Stem Cells By Application Regenerative Medicine Neurology Orthopaedics Oncology Haematology Cardiovascular and Myocardial Infraction Injuries Diabetes Liver Disorder Incontinence Others Drug Discovery & Development By Technology Cell Acquisition Bone Marrow Harvest Umbilical Blood Cord Apheresis Cell Production Therapeutic Cloning In vitro Fertilization Cell Culture Isolation Cryopreservation Expansion and Sub-culture By Therapy Autologous Allogenic By Region North America Europe Asia Pacific Latin America Middle East & Africa Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects for stem cell market SWOT analysis Key trends in stem cell regeneration techniques Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the stem cell market by technology, by product, by application, by therapy and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencie Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Stem Cell Market is estimated to value over USD 15.5 billion by 2027 end and is expected to register a CAGR over 8.5% during the forecast period 2020 to 2027.
Market Insights:
Advanced research in the development of biomaterial polymeric systems has resulted in a significant rise in recent years. These systems are instrumental in aiding the survival of stem cells which has boosted the market growth. Furthermore, advancements in the treatment of damaged tissues and diseased organs coupled with an increasing demand for regenerative medicines has propelled the market growth significantly.
The adoption of stem cell has opened new opportunities for applications such as wound healing therapy which has assisted in the further augmentation of the market. The increased supply of biomaterial development used in stem cell transplantation and induced pluripotent stem cells (iPSCs) has revolutionised the stem cell sector. Such innovations allow researchers to create pluripotent stem cells from adult somatic cells which aid in preserving genetic information in these cells thus boosting the market growth.
Based on the type of product, the market is categorised as adult stem cells, human embryonic stem cells, induced pluripotent stem cells and very small embryonic-like stem cells. The adult stem cell segment accounts for the largest market share and is predicted to continue this dominance during the forecast period. This is due to the low contamination risks linked to the minimal requirement of production labour, compatibility with the human body and sub-culturing.
Pharmaceutical companies have profitable opportunities in the stem cell sector by initiating advancements in the identification of leading candidates thus allowing companies to develop novel drugs. Furthermore, extensive research has advanced the analysis of single-cell thus helping study the effects of drugs on cell differentiation. Additionally, the growing dependence of developing entities in cellular systems is projected to help the segment strengthen its market position in the upcoming years.
Technology-wise, the market is bifurcated into cell acquisition, bone marrow harvest, apheresis, umbilical blood cord, cell production, therapeutic cloning, in-vitro fertilization, cell culture, isolation, expansion & sub-culture and cryopreservation. The cell production technology held the largest market share due to the current technological advancements aiming at satisfying the growing needs from different clinical applications. A soaring number of organ replacement approaches coupled with the rising demand for therapeutics has bolstered the market significantly. For instance, approximately 2200 transplant surgeries that were conducted in 2016 across the world were pancreas transplants.
Depending on the type of therapy, the market is fragmented into autologous stem cell therapy and allogeneic stem cell therapy.
Autologous stem cell therapy dominated the market concerning revenue generation in 2018. This is mainly attributed to the consumption of autologous products on a large scale owing to associative high compatibility. Additionally, meta-analytical studies on the effectiveness of autologous therapy for the treatment of lower limb disorders will propel the market further. Many companies are engaged in developing these autologous products for patients with sport-related injuries despite it being scrutinized by multiple government bodies.
Regional Insights:
The Asia Pacific region is projected to attain a remarkable CAGR over the forecast period. Developed economies like Australia, Singapore and Japan are extensively investing in the research and development projects which shall drive the market growth. Asia Pacific countries are likely to lead the rapidly evolving stem cell industry. Commercialization opportunities coupled with favourable regulatory policies bolster the market expansion. Japan, in particular, has initiated regulatory amendments related to regenerative medicine which has attracted international manufacturers to invest massively in the Japanese market.
Key market players include Stemcell Technologies Inc., Celegene Corp., Osiris Therapeutics Inc., Biotime Inc., Advanced Cell Technology Inc. Cytori Therapeutics, Human Longevity Inc., Cynata, Promethera Biosciences, Mesoblast., Celgene Corporation, ReNeuron Group plc, Cytori Therapeutics, Inc., Cryo-Cell International Inc.
Market Segmentation:
By Product
By Application
By Technology
By Therapy
By Region
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Stem Cell Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Stem Cell Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Stem Cell Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Stem Cell Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Stem Cell Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million) 7.1 Adult Stem Cells 7.2 Human Embryonic Stem Cells 7.3 Induced Pluripotent Stem Cells (iPSCs) 7.4 Very Small Embryonic-like Stem Cells 8. Global Stem Cell Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Regenerative Medicine 8.1.1. Neurology 8.1.2. Orthopaedics 8.1.3. Oncology 8.1.4. Haematology 8.1.5. Cardiovascular and Myocardial Infraction 8.1.6. Injuries 8.1.7. Diabetes 8.1.8. Liver Disorder 8.1.9. Incontinence 8.1.10. Others 8.2. Drug Discovery & Development 9. Global Stem Cell Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Cell Acquisition 9.1.1. Bone Marrow Harvest 9.1.2. Umbilical Blood Cord 9.1.3. Apheresis 9.2. Cell Production 9.1.1. Therapeutic Cloning 9.1.2. In vitro Fertilization 9.1.3. Cell Culture 9.1.4. Isolation 9.3. Cryopreservation 9.4. Expansion and Sub-culture 10. Global Stem Cell Market, By Therapy Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Autologous 10.2. Allogenic 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 16.1 STEMCELL Technologies Inc., 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 Celegene Corp. 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 Osiris Therapeutics Inc. 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 BIOTIME Inc. 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Advanced Cell Technology Inc. 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Cytori Therapeutics 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 Human Longevity Inc. 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 Cynata 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 Promethera Biosciences 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10 Mesoblast 16.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11 Celgene Corporation 16.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12 ReNeuron Group plc 16.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13 Cytori Therapeutics, Inc. 16.13.1. Company Overview (HQ, Business Segments, Employee Strength) 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14 Cryo-Cell International Inc. 16.14.1. Company Overview (HQ, Business Segments, Employee Strength) 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics